Human infants have limited motor capabilities, which prevents them from accessing and exploring all parts of their ...
Ionis has announced the design for a Phase III trial of ION582, a treatment for Angelman syndrome (AS), following discussions with the FDA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback